Search Results
Obinutuzumab increases survival in CLL patients with comorbidities
Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreat...
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
CLL11 trial: tackling tough-to-treat CLL patients with co-morbidities
EHA 2013: Adding obinutuzumab or rituximab to chlorambucil improves chronic lymphocytic leukaemia
Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia
CLL11 trial shows improved OS rates in CLL with obinutuzumab
Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL
Dr. Flynn on Obinutuzumab for the Treatment of CLL
